Can acne drug or hormone shots help men with low sperm count?
NCT ID NCT07481370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two treatments—isotretinoin (an acne medication) and hCG (a hormone)—to see if they can help men with low or no sperm count produce moving sperm. About 100 men aged 19 to 50 will take one of the drugs for three months. The goal is to find new options for male infertility when standard treatments don't work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isotretinoin and human chorionic gonadotropin (hCG)
- What this could lead to
- If successful, this could point toward a new treatment option for men with infertility due to low or absent sperm production.
- What could go wrong
- This is a small, early-phase study with only 100 participants. The treatments may not improve sperm production, and side effects from the medications are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AZOOSPERMIA, NONOBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 'Abnormal' embryos still lead to healthy pregnancies? a new registry investigates
- Building a biological treasure trove to decode Women's health mysteries
- Can a sperm 'Quality Check' boost IVF success?
- Foam ultrasound for fertility checks: will women find it comfortable?
- A Hormone's hidden power: could progesterone be the key to unexplained infertility?
- A questionnaire to empower fertility patients — a pilot study puts it to the test